OTCMKTS:NEPH - Nephros Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.5701 -0.01 (-1.72 %) (As of 01/16/2019 03:57 PM ET)Previous Close$0.58Today's Range$0.55 - $0.5952-Week Range$0.3803 - $0.73Volume36,000 shsAverage Volume22,307 shsMarket Capitalization$33.85 millionP/E Ratio-11.40Dividend YieldN/ABeta0.88 ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; and hemodiafilters for use as dialyzers in an hemodialysis treatment, as well as other disposables for use in the hemodiafiltration treatment process. The company was founded in 1997 and is headquartered in South Orange, New Jersey. Receive NEPH News and Ratings via Email Sign-up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NEPH Previous SymbolNASDAQ:NEPH CUSIPN/A Webwww.nephros.com Phone201-343-5202Debt Debt-to-Equity Ratio0.13 Current Ratio5.81 Quick Ratio4.81Price-To-Earnings Trailing P/E Ratio-11.40 Forward P/E Ratio-11.40 P/E GrowthN/A Sales & Book Value Annual Sales$3.81 million Price / Sales9.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book14.25Profitability EPS (Most Recent Fiscal Year)($0.05) Net Income$-800,000.00 Net Margins-25.82% Return on Equity-82.57% Return on Assets-49.16%Miscellaneous Employees15 Outstanding Shares64,170,000Market Cap$33.85 million OptionableNot Optionable Nephros (OTCMKTS:NEPH) Frequently Asked Questions What is Nephros' stock symbol? Nephros trades on the OTCMKTS under the ticker symbol "NEPH." How were Nephros' earnings last quarter? Nephros, Inc. (OTCMKTS:NEPH) issued its quarterly earnings results on Thursday, November, 8th. The company reported ($0.01) EPS for the quarter. The business earned $1.72 million during the quarter. Nephros had a negative net margin of 25.82% and a negative return on equity of 82.57%. View Nephros' Earnings History. When is Nephros' next earnings date? Nephros is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Nephros. Has Nephros been receiving favorable news coverage? News coverage about NEPH stock has trended somewhat negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nephros earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the immediate future. Who are some of Nephros' key competitors? Some companies that are related to Nephros include Sensus Healthcare (SRTS), RA Medical Systems (RMED), STRATA Skin Sciences (SSKN), Alphatec (ATEC), iCAD (ICAD), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Endologix (ELGX), Apollo Endosurgery (APEN), Motus GI (MOTS), Repro-Med Systems (REPR), CAS Medical Systems (CASM), Spectral Medical (EDTXF), Pro-Dex (PDEX) and Obalon Therapeutics (OBLN). Who are Nephros' key executives? Nephros' management team includes the folowing people: Mr. Daron G. Evans, Pres, CEO & Director (Age 44)Mr. Andrew Astor, Chief Financial Officer (Age 61)Ms. Joleen C. Turner, VP of Marketing and VP of Bus. Devel.Mr. Shane Sullivan, Director of North American SalesMs. Monet Carnahan RN, BSN,CDN, Director of Dialysis Products How do I buy shares of Nephros? Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nephros' stock price today? One share of NEPH stock can currently be purchased for approximately $0.5701. How big of a company is Nephros? Nephros has a market capitalization of $33.85 million and generates $3.81 million in revenue each year. The company earns $-800,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Nephros employs 15 workers across the globe. What is Nephros' official website? The official website for Nephros is http://www.nephros.com. How can I contact Nephros? Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202. MarketBeat Community Rating for Nephros (OTCMKTS NEPH)Community Ranking: 1.8 out of 5 ()Outperform Votes: 44 (Vote Outperform)Underperform Votes: 79 (Vote Underperform)Total Votes: 123MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote "Outperform" if you believe NEPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: Do Tariffs Work?